{"title":"Risk factors and prediction model for cancer-related cognitive impairment in thyroid cancer patients.","authors":"Ting Ni, Jie Sun, Qin He, Yuning Dai, Xiaobei Wang, Enqiao Yu, Guodong Shen","doi":"10.62347/AOTU1301","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment is a common, yet often overlooked, complication in thyroid cancer patients, potentially influenced by various demographic, clinical, biochemical, and psychological factors. This study aims to analyze the prevalence and determinants of cancer-related cognitive impairment (CRCI) in thyroid cancer patients.</p><p><strong>Methods: </strong>A retrospective case-control study was conducted involving 246 thyroid cancer patients treated at our The First Affiliated Hospital of Soochow University from January 2021 to January 2023. Patients were categorized into high cognitive function (n = 125) and low cognitive function groups (n = 121) based on Mini Mental State Examination (MMSE) scores. Data were collected on demographic variables, Charlson Comorbidity Index (CCI), disease duration, clinical stage, blood test results, inflammatory factors (interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP)), psychological status (Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), Self-Esteem Scale (SES)), sleep quality (Pittsburgh Sleep Quality Index (PSQI)), and quality of life (36-item Short-Form Health Survey (SF-36)). Additionally, an external validation set was established, with patients being divided into a high cognitive level group (n = 135) and a low cognitive level group (n = 128), and the model's predictive performance was validated through the external dataset.</p><p><strong>Results: </strong>Factors significantly associated with lower cognitive function included age (P < 0.001), education level (P < 0.001), CCI scores (P < 0.001), disease duration (P < 0.001), clinical stage (P = 0.003), IL-6 (P < 0.001), IL-8 (P = 0.005), TNF-α (P < 0.001) and CRP (P < 0.001). SDS (P < 0.001), SAS (P < 0.001) and PSQI (P < 0.001) were also associated with reduced cognitive function. The Least Absolute Shrinkage and Selection Operator (LASSO) regression model demonstrated strong predictive performance with an area under the curve (AUC) of 0.903 in the training set and an AUC of 0.835 in the validation set.</p><p><strong>Conclusion: </strong>CRCI in thyroid cancer patients is multifactorial, with significant contributions from demographic, clinical, inflammatory, and psychological factors. The developed predictive model may serve as a valuable tool in clinical practice for identifying thyroid cancer patients at high risk of cognitive impairment.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 1","pages":"153-167"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815387/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/AOTU1301","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cognitive impairment is a common, yet often overlooked, complication in thyroid cancer patients, potentially influenced by various demographic, clinical, biochemical, and psychological factors. This study aims to analyze the prevalence and determinants of cancer-related cognitive impairment (CRCI) in thyroid cancer patients.
Methods: A retrospective case-control study was conducted involving 246 thyroid cancer patients treated at our The First Affiliated Hospital of Soochow University from January 2021 to January 2023. Patients were categorized into high cognitive function (n = 125) and low cognitive function groups (n = 121) based on Mini Mental State Examination (MMSE) scores. Data were collected on demographic variables, Charlson Comorbidity Index (CCI), disease duration, clinical stage, blood test results, inflammatory factors (interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP)), psychological status (Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), Self-Esteem Scale (SES)), sleep quality (Pittsburgh Sleep Quality Index (PSQI)), and quality of life (36-item Short-Form Health Survey (SF-36)). Additionally, an external validation set was established, with patients being divided into a high cognitive level group (n = 135) and a low cognitive level group (n = 128), and the model's predictive performance was validated through the external dataset.
Results: Factors significantly associated with lower cognitive function included age (P < 0.001), education level (P < 0.001), CCI scores (P < 0.001), disease duration (P < 0.001), clinical stage (P = 0.003), IL-6 (P < 0.001), IL-8 (P = 0.005), TNF-α (P < 0.001) and CRP (P < 0.001). SDS (P < 0.001), SAS (P < 0.001) and PSQI (P < 0.001) were also associated with reduced cognitive function. The Least Absolute Shrinkage and Selection Operator (LASSO) regression model demonstrated strong predictive performance with an area under the curve (AUC) of 0.903 in the training set and an AUC of 0.835 in the validation set.
Conclusion: CRCI in thyroid cancer patients is multifactorial, with significant contributions from demographic, clinical, inflammatory, and psychological factors. The developed predictive model may serve as a valuable tool in clinical practice for identifying thyroid cancer patients at high risk of cognitive impairment.
期刊介绍:
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.